The researchers added that this reveals an interesting area for studying the treatment of chronic infection with HIV "H.I.V.", according to Archyde.com.
Currently, antiretroviral therapies allow for many people infected with HIV "H.I.V." To lead a normal life, but drugs do not mean the body gets rid of virus In full, the remaining stock of virus means that patients have not really recovered from the infection.
and real estate "Keytruda", also known as "pembrolizumab", a monoclonal antibody designed to help immune system In the body, it fights cancer by blocking a protein known as a programmed death receptor that tumors use to evade disease-fighting cells.
These drugs work by releasing molecular brakes or checkpoints that tumors use to evade the body’s immune system, allowing immune cells to recognize and attack cancer cells in the same way they would fight infection with bacteria or viruses.
An international team of researchers said it had found evidence that these drugs are able to neutralize the HIV latency, the ability of the virus to kill. "hiding" Inside the cells of symbionts depending on antiviral treatment.
The study, published Wednesday in Science Translational Medicine, included 32 people with both cancer and HIV through the Fred Hutchinson Cancer Research Center in Seattle.
The participants were also being treated with effective antiviral drugs to suppress HIV.
Professor Sharon Lewin, Director of the Peter Duarte Institute for Infection and Immunology in Melbourne, Australia, said in a statement. "Pembrolizumab is capable of disrupting the HIV reservoir".
Her group examined blood samples from study participants before and following the treatment.
Lewin said work on these samples will continue to understand how the drug modulates the immune response to HIV.
“>
Researchers conducting a study on the use of the drug “Keytruda”, which is produced by the “Merck” company, to treat cancerfor patients with HIV, which causes diseaseAIDSAlso, with cancer, immunotherapy may also help flush the virus out of human immune cells.
The researchers added that this reveals an interesting area for studying the treatment of chronic infection with the “HIV” virus, according to what Archyde.com reported.
Currently, antiretroviral therapies allow many people with HIV to lead normal lives, but the drugs do not mean the body gets rid of the virus. virus In full, the remaining stock of virus means that patients have not really recovered from the infection.
Keytruda, also known as pembrolizumab, is a monoclonal antibody designed to help immune system In the body, it fights cancer by blocking a protein known as a programmed death receptor that tumors use to evade disease-fighting cells.
These drugs work by releasing molecular brakes or checkpoints that tumors use to evade the body’s immune system, allowing immune cells to recognize and attack cancer cells in the same way they would fight infection with bacteria or viruses.
An international team of researchers said that it had found evidence that these drugs are able to nullify the latency of the HIV virus, that is, the virus’s ability to “hide” inside the cells of people living with it, depending on an antiviral treatment.
The study, published Wednesday in Science Translational Medicine, included 32 people with both cancer and HIV through the Fred Hutchinson Cancer Research Center in Seattle.
The participants were also being treated with effective antiviral drugs to suppress HIV.
“Pimbrolizumab has the potential to disrupt the HIV reservoir,” Professor Sharon Lewin, director of the Peter Duarte Institute for Infection and Immunology in Melbourne, Australia, said in a statement.
Her group examined blood samples from study participants before and following the treatment.
Lewin said work on these samples will continue to understand how the drug modulates the immune response to HIV.
/origin-imgresizer.eurosport.com/2024/09/14/4039906-81935768-2560-1440.jpg?fit=300%2C300&ssl=1)
